Copies of the final prospectus supplement and the accompanying base prospectus may be obtained for free by contacting Newbridge Securities Corporation, Attn: Equity Syndicate Department, 1200 North Federal Highway, Suite 400, Boca Raton, FL 33432, by email at This email address is being protected from spambots. Gains lead drug candidate GT-02287, in development for the treatment of GBA1 Parkinsons disease, is currently being evaluated in a Phase 1 clinical trial.Leveraging AI-supported structural biology, proprietary algorithms and supercomputer-powered physics-based models, the companys SEE-Tx\xae discovery platform can identify novel allosteric binding sites on disease-implicated proteins, pinpointing pockets that cannot be found or drugged with current technologies. Gains unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect managements current knowledge, assumptions, judgment and expectations regarding future performance or events.